clinical trial · NCT03435796
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Celgene·phase3·recruiting·n = 1,541
NeoplasmsGene-modified (GM) T cell therapy
brief summary
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.
started
Jul 19, 2018
primary completion
Nov 30, 2036
completion
Nov 30, 2036
last updated
Mar 4, 2026
official title
Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol